Page 1

Compass NEWS RELEASE COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021 2021-05-13 Highlights : New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder • Two further US patents granted • Equity financing raises gross proceeds of $ 144 million • Phase llb clinical trial of COMP360 psilocybin therapy for treatment - resistant depression ( TRD ) on track to report data by end of 2021 • Wayne J Riley MD joins Board of Directors and Anne Benedict is appointed Chief People Officer Conference call today at 1:00 pm UK ( 8:00 am ET ) LONDON , May 13 , 2021 ( GLOBE NEWSWIRE ) -- COMPASS Pathways plc ( Nasdaq : CMPS ) ( " COMPASS " ) , a mental health care company dedicated to accelerating patient access to evidence - based innovation in mental health , today reported its financial results for the first quarter 2021 and gave an update on recent progress across its business . George Goldsmith , Chairman , CEO and Co - founder , COMPASS Pathways , said , " Our recent financing gives us additional resources to work even faster and to expand our efforts , grow our team , and focus on developing new indications , new compounds and new technologies , building on our leadership position in psilocybin therapy and mental health care . Far too many people are suffering with mental health challenges today . We are focused on developing evidence - based therapies that can make a difference and be accessible to as many patients as possible who might benefit . The COMP360 data published in the New England Journal of Medicine showed promising signals in a small investigator - initiated study . We are approaching the completion of our phase llb trial of COMP360 psilocybin therapy for treatment - resistant depression , and on track to report data by the end of the year . " 1